Long-term follow up of sustained viral response after treatment of hepatitis C with pegylated interferon α-2a in hemodialysis patients

International Journal of Artificial Organs

Volumn 32, Issue 3, 2009, Pages 180-184

  Dzekova, Pavlina ^a   Asani, Arben ^a   Selim, Gjulsen ^a   Gelev, Saso ^a   Trajceska, Lada ^a   Amitov, Vili ^a   Selja, Nexheni ^b   Zabzun, Mustafa ^b   Mena, Sami ^b   Gaseva, Magdalena ^c   Sikole, Alexander ^a  

^a University Clinic of Nephrology   (Macedonia)

^b Institute of Nephrology   (Macedonia)

^c University Clinic of Infectious Diseases   (Macedonia)

Author keywords

Hemodialysis; Hepatitis C; Pegylated interferon 2a; Sustained viral response

Indexed keywords

ANTIBIOTICS; ANTIBODIES; CHAINS; GLYCOPROTEINS; HEMODIALYZERS; PATIENT TREATMENT; POLYMERASE CHAIN REACTION; RNA; VIRUSES;

AFTER-TREATMENT; FOLLOW UP; HAEMODIALYSIS; HCV RNA; HEMODIALYSIS PATIENT; HEPATITIS C; LONG-TERM FOLLOW-UP; PEGYLATED; PEGYLATED INTERFERON Α-2A; SUSTAINED VIRAL RESPONSE;

DIALYSIS;

HEMOGLOBIN; HEPATITIS C ANTIBODY; PEGINTERFERON ALPHA2A; RECOMBINANT ERYTHROPOIETIN; VIRUS RNA;

ADULT; ANALYTICAL PARAMETERS; ARTICLE; BRAIN HEMORRHAGE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GENOTYPE; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBINOPATHY; HEPATITIS C; HUMAN; HYBRIDIZATION; LEUKOCYTE COUNT; LONG TERM CARE; MALE; PERICARDITIS; PNEUMONIA; PROSPECTIVE STUDY; RELAPSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIDE EFFECT; THROMBOCYTE COUNT;

EID: 67650679380     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880903200309     Document Type: Article

References (18)

1. Morales JM, Campistol JM. Transplantation in the patient with hepatitis C. J Am Soc Nephrol 2000; 11: 1343-53.
2. Cross TJS, Antoniades CG, Harrison PM. Current and future management of chronic hepatitis C infection. Postgrad Med J 2008; 84: 172-6.
3. Fabrizi F, Dixit V, Messa P, Martin P. Interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials. J Viral Hepat 2008: 15 (2): 79-88.
4. Gordon CE, Uhlig K, Lau J, Schmid CH, Levey AS, Wong JB. Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms. Am J Kidney Dis 2008: 51: 263-77.
5. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666-72.
6. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
7. Sikole A, Dzekova P, Selja N, et al. Treatment of Hepatitis C in Hemodialysis Patients with Pegylated Interferon α-2a as Monotherapy. Ren Fail 2007; 29: 961-6.
8. Fabrizi F, Lunghi G, Martin P. Treatment of HCV related liver disease in the dialysis population: a novel challenge for clinical nephrologists. Int J Artif Organs 2001; 24: 335-45.
9. Rostaing L, Chatelut E, Payen JL, et al. Pharmacokinetics of alpha IFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. J Am Soc Nephrol 1998; 9: 2344-8.
10. Ucmak H, Kokoglu OF, Hosoglu S, et al. Long-term efficacy of pegylated interferon alpha-2a in HCV-positive hemodialysis patients. Ren Fail 2008; 30: 227-32.
11. Fabrizi F, Lunghi G, Ganeshan SV, Martin P, Messa P. Hepatitis C virus infection and the dialysis patient. Semin Dial 2007; 20: 416-22.
12. Liu CH, Liang CC, Lin JW et al. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut 2008; 57: 525-30.
13. Shiratori Y, Imazeki F, Moriyama M, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000; 132: 517-24.
14. Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999;131: 174-81.
15. Contreras AM, Ruiz I, Polanco-Cruz G, et al. End-stage renal disease and hepatitis C infection: comparison of alanine aminotransferase levels and liver histology in patients with and without renal damage. Ann Hepatol 2007; 6: 48-54.
16. Lopes EP, Gouveia EC, Albuquerque AC, et al. Determination of the cut-off value of serum alanine aminotransferase in patients undergoing hemodialysis, to identify biochemical activity in patients with hepatitis C viremia. J Clin Virol 2006; 35: 298-302.
17. Fabrizi F, Lunghi G, Finazzi S, et al. Decreased serum aminotransferase activity in patients with chronic renal failure: impact on the detection of viral hepatitis. Am J Kidney Dis 2001; 38: 1009-15.
18. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137: 1-10.